Roschier represents Karo Pharma in connection with EQT’s public cash offer to the shareholders in the company
EQT, through EQT VIII and Karo Intressenter AB, has announced a public cash offer to the shareholders in Karo Pharma Aktiebolag to acquire the shares in Karo Pharma not already owned by Karo Intressenter. Roschier represents Karo Pharma in connection with the offer.
Karo Pharma offers “Smart choices for everyday healthcare”. The company owns and commercializes reliable original brands within prescription drugs and over-the-counter consumer products, available in over 90 countries with the core in Europe and the Nordic region. Karo Pharma is headquartered in Stockholm and listed on Nasdaq First North Growth Market.
EQT is a purpose-driven global investment organization with EUR 77 billion in assets under management across 36 active funds. EQT funds have portfolio companies in Europe, Asia-Pacific and the Americas with total sales of approximately EUR 29 billion and more than 280,000 employees. EQT works with portfolio companies to achieve sustainable growth, operational excellence and market leadership.
Roschier’s advisory group comprises Partners Jens Bengtsson and Ola Sandersson, Senior Associate Erik Persson and Associate Ellen Pettersson.